BioMarin Pharma (BMRN) Tops Q3 EPS by 5c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BioMarin Announces Third Quarter 2015 Financial Results and Company Update
October 29, 2015 4:03 PM EDT- Vimizim Net Product Revenue $65 million in the Quarter; Vimizim Full-year Revenue Guidance Increased to $220 to $235 million
- Full-year Total BioMarin Revenue Guidance Increased to $880 million to $900 million
- FDA Advisory Committee to Review Kyndrisa (drisapersen) November 24th for Treatment of Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Financial Highlights ($ in millions, except per share data, unaudited)Â
 Three MonthsEnded September... More